This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    MD Capsule: Renal Cell Carcinoma

    RCC Guideline for Follow-Up

    Based on National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) recommendations.

    Select a TNM Stage for RCC and treatment/workups (optional) to see the NCCN/AUA recommendations below. Note: this summary table is meant to simplify the guideline recommendations for bedside use. It is not intended to replace them, or to be a comprehensive reference, and users should refer to the full guidelines (links below) for details and caveats.

    Show All
    ×
    Workup
    For a Stage I / Stage II or III / Relapsed or Unresectable Stage IV patient undergoing Active Surveillance / Ablation / Partial or Radical Nephrectomysee the table for follow-up.
    Copy Results
    Table
    Next Steps
    Evidence
    Creator Insights
    Related Calcs
    About the Creator
    Dr. Sherri M. Donat
    Are you Dr. Sherri M. Donat?
    Dr. Robert J. Motzer
    Are you Dr. Robert J. Motzer?
     = Can do workup at any time within blue range
     = Should do workup at specific time marked

    One box corresponds to 3 months time

    Years012345
    Stage I
    Active Surveillance
    H & P
    CMP, etc.
    CT/MR Abd
    Ultrasound acceptable after initial imaging with CT or MRI
    CT/XR Chest
    If biopsy-proven RCC or oncocytic features
    CT/MR Pelvisas clinically indicated
    CT/MR Head/MR Spineas clinically indicated
    Bone Scanas clinically indicated
    Ablation
    H & P
    CMP, etc.
    CT/MR Abd*
    Ultrasound acceptable after initial imaging with CT or MRI
    CT/MR Abd*
    Ultrasound acceptable after initial imaging with CT or MRI
    CT/XR Chest
    If biopsy-proven low risk RCC, nondiagnostic biopsy, or no prior biopsy
    Repeat BiopsyIf new enhancement, progressive increase in size, new nodularity, failure to regress, or satellite or port site lesions
    CT/MR Pelvisas clinically indicated
    CT/MR Head/MR Spineas clinically indicated
    Bone Scanas clinically indicated
    Partial or Radical Nephrectomy
    H & P
    CMP, etc.
    CT/MR/US Abd
    CT/MR/US Abdthen at physician's discretion
    CT/XR Chest
    CT/MR Pelvisas clinically indicated
    CT/MR Head/MR Spineas clinically indicated
    Bone Scanas clinically indicated
    Stage II or III
    Radical Nephrectomy
    H & P
    CMP, etc.
    CT/MR Abd*
    Ultrasound acceptable after initial imaging with CT or MRI
    CT/MR Abd*
    Ultrasound acceptable after initial imaging with CT or MRI
    CT Chest*
    XR Chest acceptable after initial imaging with CT
    CT/MR Chest*
    XR Chest acceptable after initial imaging with CT or MRI
    CT/MR Pelvisas clinically indicated
    CT/MR Head/MR Spineas clinically indicated
    Bone Scanas clinically indicated
    Relapsed or Unresectable Stage IV
    H & Pevery 6 - 16 weeks, or as clinically indicated
    Labsper requirements for type of chemotherapy being used
    C/A/P Imagingevery 6 - 16 weeks, per physician discretion and patient's clinical status
    CT/MR Headat baseline then as clinically indicated, annually at physician's discretion
    MR Spineas clinically indicated
    Bone Scanas clinically indicated